NORO-MOSELEY PARTNERS
NORO-MOSELEY PARTNERS is a Series A, Series C+ and seed-plus fund in the US and Southeastern US writing $5M–$20M checks into Enterprise and healthcare-tech.
- Stages
- Series A, Series C+, seed-plus
- Sectors
- Enterprise, healthcare-tech
- Check size
- $5M–$20M
- Invests in
- US-wide, Southeastern US
- Round role
- Leads rounds
- Actively investing
- Yes
- Founded
- 1983
- Assets under management
- $634M
- Website
- noromoseley.com
Thesis
Noro-Moseley Partners (NMP) is a venture capital firm founded in 1983, headquartered in Atlanta, Georgia, with approximately $634 million in AUM. The firm focuses on early growth equity investments in B2B technology and healthcare sectors, targeting companies with strong management teams and significant market disruption potential. NMP's investment strategy involves identifying high-growth companies demonstrating year-over-year growth of 50% or more, with unit economics and a revenue run rate between $2 million and $20 million. They typically invest $5 million to $20 million per deal, often leading investments and being the first institutional capital for Series A rounds. Their geographic scope is primarily the United States, with a strong emphasis on the Southeastern region. NMP VIII, their eighth fund, closed in May 2019 at $180 million, their largest since the dot-com boom.
Common questions
Does NORO-MOSELEY PARTNERS invest at the Series A stage?
Yes. NORO-MOSELEY PARTNERS lists Series A, Series C+ and seed-plus among the stages it invests in.
What check size does NORO-MOSELEY PARTNERS write?
NORO-MOSELEY PARTNERS writes $5M–$20M checks.
Where does NORO-MOSELEY PARTNERS invest?
NORO-MOSELEY PARTNERS invests in the US and Southeastern US.